News & Updates

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Although the COVID-19 pandemic is over, the disease remains a threat as it is predicted to become a significant danger to public health in the next 2 years, particularly in the US, according to a study. Wide-ranging vaccination, however, can counter this potential problem.